bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Direct measurement of B lymphocyte gene expression biomarkers in peripheral
blood enables early prediction of seroconversion after vaccination.
Dan Huang 1, Alex YN Liu 1, K.S. Leung 2, Nelson LS Tang 3
1

Cytomics Limited, Hong Kong Science and Technology Park, Hong Kong
Department of Computer Science and Engineering, The Chinese University of Hong Kong
3
Department of Chemical Pathology and Li Ka Shing Institute of Health Science, The Chinese University of
Hong Kong
2

Abstract
Vaccination is a common and efficient means to reduce the mortality and morbidity of emerging
infectious diseases. Among responders, injected antigen induces acquired immunity pathways and leads to the
final production of antigen-specific antibodies. The whole process may take weeks to months, depending on the
antigen. Typically, seroconversion to influenza vaccine is expected after one month with a responder rate of
~50%.
An early biomarker to predict response is desirable. Peripheral blood gene expression (or transcript
abundance, TA) datasets in the public domain were analyzed for early biomarkers among responders. As
peripheral blood samples (such as peripheral blood mononuclear cells, PBMC) are cell mixture samples
containing various blood cell-types (leukocyte subpopulations, LS). We first develop a model that enables the
determination of TA in B lymphocytes of certain genes directly in PBMC samples without the need of prior cell
isolation. These genes are called B cell informative genes. Then a ratio of two B cell informative genes (a target
gene and a stably expressed reference gene) measured in PBMC was used as a new biomarker to gauge the
target gene expression in B lymphocytes. This method having an obvious advantage over conventional methods
by eliminating the tedious procedure of cell sorting and enables directly determining TA of a leukocyte
subpopulation in cell mixture samples is called Direct LS-TA method.
By using a B lymphocyte-specific gene such as TNFRSF17 or TXNDC5 as target genes with either
TNFRSF13C or FCRLA as reference genes, the B cell biomarkers were determined directly in PBMC which
was highly correlated with TA of target genes in purified B lymphocytes. These Direct LS-TA biomarkers in
PBMC increased significantly early after vaccination in both the discovery dataset and a meta-analysis of 7
datasets. Responders had almost a 2-fold higher Direct LS-TA biomarker level of TNFRSF17 (SMD=0.84, 95%
CI=0.47-1.21 after log2). And Direct LS-TA biomarkers of TNFRSF17 and TXNDC5 measured at day 7
predict responder with sensitivity values of higher than 0.7. The Area-under curves (AUC) in receiver operation
curve (ROC) analysis were over 0.8.
Here, we report a straightforward approach to directly analyses B lymphocyte gene expression in
PBMC, which could be used in a routine clinical setting as it avoids the labor-intensive procedures of B
lymphocyte isolation. And the method allows the practice of precision medicine in the prediction of vaccination
response.
Furthermore, response to vaccination could be predicted as early as on day 7. As vaccination response is
based on the similar acquired immunology pathway in the upcoming worldwide vaccination campaign against
COVID-19, these biomarkers could also be useful to predict seroconversion for individuals.

Keywords:
Vaccination, seroconversion, B lymphocytes, gene expression, Transcript abundance, influenza, COVID-19,
biomarker, peripheral blood
P a g e 1 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Background
Vaccination by a prior exposure (injection) of an antigen or its precursor is a good strategy for controlling
infection and epidemics. Such prior exposure activates the acquired immune system to produce antibody against
the pathogen before getting exposed to the pathogen and a full-blown infection. In vaccinated individuals, the
pathogens will be controlled quickly, and symptoms of infection are largely reduced or even asymptomatic. A
common example is vaccination against the influenza virus. As the prevalent strains of influenza virus change
frequently, annual vaccination of different influenza virus strains is commonly practiced in many parts of the
World. Of particular relevance is the current pandemic COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), against which a Worldwide vaccination campaign is also underway.
In the case of vaccination against the influenza virus, just only more than 50% of vaccinated individuals mount
an immune response and are protected from subsequent infection. They are called responders (R) to vaccination
and are characterized by a having substantial production of antibodies against the antigen injected through the
vaccination (seroconversion). On the other hand, the remaining individual with insufficient antibody
production and not protected from the virus are called non-responders (NR). Antibody production is measured
as titers of antibodies against the vaccination antigen in blood samples taken 28 days after vaccination (Mo et
al., 2017). Typically, the reported responder (seroconversion) rate after influenza vaccination is less than 50%
of subjects received the vaccination. Furthermore, the responder status will only be known 28 days after
vaccination as it takes time for the acquired immune system to produce antibodies against immunization
antigen. In order to practice precision medicine of vaccination, and to be better informed of the risk of infection,
a better biomarker that can make an early prediction is desirable.
Gene expression profile and changes after vaccination have been studied in various vaccination trials towards
different pathogens, including influenza, tuberculosis, hepatitis, and yellow fever (Casey et al., 2019; Henn et
al., 2013; Nakaya et al., 2011; Tsang et al., 2014). Most studies measured gene expression or transcript
abundance (TA) in a peripheral blood sample, and few of them also did it on purified leukocyte cell-types
(Henn et al., 2013). Systemic biology approaches have been applied to study the complexity problem of
molecular signatures after vaccination, which is largely confounded by the presence of various leukocyte
subpopulations in clinical samples, reviewed by (Pezeshki et al., 2019). Previous studies of TA after vaccination
were limited to either focusing on the determinants among responders or the difference between vaccination and
a full-blown infection (Rogers et al., 2019). These studies provided a comprehensive list of differential
expression genes (DEG) typically composed of tens or hundreds (Henn et al., 2013) genes which were
attributed to various pathways (such as interferon or other cytokine response) by gene enrichment analysis. To
derive a useful biomarker from a long list of DEG is troublesome both in terms of the applied analysis method
has to quantify many genes and lack of clear understanding of the cellular origin of these gene transcripts.
Furthermore, most of them used peripheral blood mononuclear cells (PBMC) to study TA in blood samples.
Other studies also used whole blood, WB (Weiner et al., 2019). Peripheral blood is composed of various
leukocyte cell-types, such as neutrophils, lymphocytes, and monocytes. So it is a kind of convoluted results
gathered from many different cell-types present in the blood mixture samples.
Against this background, gene expression (TA) of a single cell-type (subpopulation) is a better biomarker. The
research community has called for a new biomarker to enhance vaccine development, particularly in view of the
current COVID-19 epidemic(Black et al., 2020; Pezeshki et al., 2019). Here, we are interested if B lymphocyte
TA could be a reliable early indicator of subsequent seroconversion as B lymphocyte/plasma cells are the
production factory of antibodies, which is the most logical choice of cell-type to follow after immunization. In
order to obtain gene expression (TA) level of a single cell-type in peripheral blood, prior isolation and
purification of the specified cell-types are required in a conventional approach which could only be carried out
P a g e 2 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

in a research laboratory setting as the purification procedure is too tedious to be used in a clinical laboratory.
More recently, another method called single-cell RNA-sequencing is also possible to obtain gene expression
information of a single cell to obtain the B cell immunoglobulin gene repertoire data (Horns et al., 2020).
Single-cell RNA-sequencing (RNA-seq) generates data of gene expression of individual single-cells
irrespective of their cell-types by use of expansive equipment and reagents which limits its large-scale
application in routine clinical care.
In order to have a better understanding of the cellular origin of a particular gene transcript in commonly used
peripheral blood mixture samples, a framework was derived to define a list of cell-type informative genes in a
peripheral blood mixture sample, in which the majority (>50%) of the transcripts are contributed by a specific
cell-type given both the extent of differential gene expression among those cell-types present in the mixture
sample and their respective cell count proportion. The framework of cell-type informative genes is better than
the conventional concept of cell-type-specific genes which are only expressed exclusively in a cell-type. Genes
with such exclusive expression profiles in the highly related hematopoietic cell-types are very limited (such as
CD19, CD20 (MS4A1) for B cells). Under a similar concept, the latest protein atlas (Uhlen et al., 2019) also has
this similar concept and called them as lineage enriched genes which are 50 such B cell lineage genes with the
highest expression in the blood (https://www.proteinatlas.org/search/blood_cell_lineage_category_rna%3Abcells%3BLineage+enriched+AND+tissue_category_rna%3ABlood%2CLymphoid+tissue%3BIs+highest+expre
ssed+AND+sort_by%3Atissue+specific+score). Here, the two terms, B lymphocytes informative genes and B
lymphocyte lineage enriched genes are used interchangeably to indicate the list of genes with higher expression
in B lymphocyte in PBMC or whole blood. A similar but not identical method has been used to determine cell
count proportions of various cellular subpopulations in a cell mixture by a mathematic model called
deconvolution which used a long panel of signature genes for each subpopulation (Avila Cobos et al., 2020;
Monaco et al., 2019; Shen-Orr et al., 2010; Shen-Orr & Gaujoux, 2013). However, our target is gene expression
(TA) of a subpopulation of interest rather than the proportional count of that subpopulation.
With the list of B lymphocyte informative genes in both PBMC and peripheral blood available, we analyzed
their expression profile in publicly available datasets of vaccination experiments. As we are interested in
identifying early B lymphocyte TA biomarkers that are predictive of the subsequent antibody response status
(seroconversion), we explore the predictive performance of TA data and the Direct LS-TA biomarkers obtained
around the first week after vaccination.

P a g e 3 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Data, Methods and Analysis Models
A detailed workflow to define B lymphocyte informative genes and Meta-analysis is shown in the
supplementary workflow document.

Datasets used in the analysis of gene expression of peripheral blood and B cells
In order to identify B lymphocyte cell-type informative genes that can predict vaccination response, the
following datasets of gene expression obtained from peripheral blood samples were used (Table 1). These
datasets were available in the Gene Expression Omnibus (GEO) maintained by the United State National
Institute of Health. The details can be obtained under their accession number. The type of blood samples
obtained are peripheral blood mononuclear cells (PBMC). In some datasets (GSE45764), further isolation and
purification of specific cell-types were performed, such as obtaining the purified B lymphocytes (Henn et al.,
2013).
There are other additional datasets of vaccination studies. However, only these datasets had individual antibody
response data, HI titer, available for us to define Responders and Non-responders.
Table 1. List of gene expression datasets of PBMC or WB used in this study
Type of
Type of
No.of No.of NonData series
vaccine Total No. of
No.of
Blood
QC Responders
accession
used
samples (all
Responders
samples(WB
failed
(NR) at
number
(against the time points)
(R ) at Day7
or PBMC)
samples
Day7
virus)
Influenza
GSE29614
PBMC
18
2
7
TIV
Influenza
GSE29615
PBMC
55
26
1
LAIV
Influenza
GSE29617
PBMC
53
2
7
19
TIV
GSE101709

PBMC

Influenza

41

4

11

8

GSE101710

PBMC

Influenza

31

-

5

10

GSE59635

PBMC

Influenza

36

1

7

10

GSE59654

PBMC

Influenza

76

3

24

14

GSE59743

PBMC

Influenza

50

-

9

11

Paired
PBMC and
GSE45764
Influenza
Purified B
lymphocytes

104

6

Reference

(Nakaya et al.,
2011)
(Nakaya et al.,
2011)
(Nakaya et al.,
2011)
(Avey et al.,
2020)
(Avey et al.,
2020)
(Thakar et al.,
2015)
(Thakar et al.,
2015)
(Thakar et al.,
2015)
(Henn et al.,
2013)

Definitions of vaccination response
Responders (R) after vaccination are defined following the criteria of seroconversion/significant increase of
anti-hemagglutinin antibody levels (HI titer) performed by hemagglutination inhibition (HI) assays on subjects‚Äô
P a g e 4 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

plasma or serum has taken before and after vaccination (commonly taken at Day 28)(Mo et al., 2017). The
European Committee for Medicinal Products for Human Use (CHMP) defines seroconversion/significant
increase as: (a) HI titer after vaccination is at least 1 in 40 and (b) there was at least four folds increase from the
pre-vaccination baseline (Committee for Medicinal Products for Human Use., 1997; Mo et al., 2017).
Individuals who did not meet these criteria after vaccination were defined as Non-responders (NR).

To define B lymphocyte informative genes whose expression level can be reliably inferred in cellmixture samples, e.g., PBMC or WB
A new model was used to incorporate a pre-defined expected proportional count of a particular cell-type (Blymphocyte in this study) in a cell-mixture sample (e.g., PBMC or WB). Although the B lymphocyte count is
variable among individuals and decreases with age (Blanco et al., 2018; Ding et al., 2018), the median
proportional cell percentage of B-lymphocyte in WB is about 5%, which is a reasonable pre-defined figure used
as an approximation of proportional count in our model (Blanco et al., 2018). Similarly, B lymphocytes are
expected to account for ~10% of cells in PBMC.
The model (Figure 1 and 2) is used to shortlist genes that are preferentially expressed by B lymphocytes to the
extent such that the sole majority contribution (>50%) of gene transcripts in a cell-mixture sample could be
attributed to B lymphocytes. In the example of WB, that is the 5% B lymphocytes component in WB as the sole
producer of the majority of gene transcripts (TA) in the WB cell-mixture sample. These genes are called celltype informative genes, in contrast to the conventional concept of cell-type-specific genes which are exclusively
produced by a particular cell-type. As transcripts and TA of those informative genes predominantly come from
a single cell-type, direct measurement of their total transcript abundance (TA) in the cell mixture sample would
be a valid estimation of the gene expression level of that component cell-type.
In order to determine if a gene is a potential B lymphocyte informative gene, it could be evaluated by its TA in
both the cell-mixture sample (e.g., WB or PBMC) and purified target cell-type (B lymphocyte) samples. As
shown in figure 2, the fold difference between purified B lymphocytes samples and WB samples can be used to
determine if a gene in WB had its majority contribution from B lymphocytes. In figure 2, target gene expression
is quantified with a housekeeping gene (HK gene), which is a common practice in quantitative PCR. It is shown
that any genes having at least 10-folds higher expression in purified B cell samples than WB samples fulfills the
criteria of potentially B lymphocyte informative genes. This approach and model is different from previous
deconvolution methods of deriving the proportional cell counts of various cell-type subpopulations, the primary
output of which are the proportional counts of various cell-types (Monaco et al., 2019; Shen-Orr & Gaujoux,
2013). On the other hand, our method is focused on direct estimation of the average gene expression (TA) of
shortlisted informative genes of a given cell-type in WB or PBMC.

P a g e 5 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 1. (A) Cell-type origin information is lost in bulk gene expression data. (B) The
conventional concept of cell-type-specific genes are those genes exclusively produced by one
particular cell-type. Such genes would be few. (C) Our new concept that genes that are
preferentially expressed by a cell-type to the extent that it is the sole major contribution (>50%) of
gene transcripts in a cell-mixture sample could be informative of gene expression (TA) of that celltype (e.g., B lymphocyte in the figure). Transcript symbols produced by various cell-types are
colored for presentation purposes only (Red for granulocyte produced transcripts and blue for Blymphocyte produced transcripts); the transcripts are, in fact, identical.

P a g e 6 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 2. A theoretical model of B lymphocyte cell-type (Square) in a WB sample (with three
different cell-types, symbolized as square, circle, and rhomboid). A pre-defined proportional
cell count of 5% is given as the proportion of B lymphocyte in WB leukocytes. When TA of a
gene was measured both in the WB and purified B lymphocyte samples, B lymphocyte
informative genes as we defined will have at least 10-folds higher expression / TA in the
purified cell sample (purified B cells) than the cell-mixture sample (WB). Measurement of TA
is based on a commonly used normalization approach using another housekeeping (HK) gene.

P a g e 7 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

A mathematical model to describe the informative gene framework
In order to understand what would be the required folds difference in TA between purified cells and cellmixture for cell-types of various proportional counts, a mathematical model was used to generalized this
concept of the cell-type informative gene to facilitate identification of cell-type informative genes for various
cell-types present in different cell-mixture samples (WB, PBMC or other tissue).
Model of % contribution of the transcript by a cell type (e.g., B cells) inside a cell mixture (e.g., WB)
Let
= total transcript abundance (TA) of a gene in a WB sample
ùëáùê¥ùëäùêµ
ùëáùê¥ùêµ ùëêùëíùëôùëôùë†
ùëÉùêµ ùëêùëíùëôùëôùë†

X

= TA of a gene in B cells present inside the WB sample
= proportional cell count of B cells inside the WB sample (e.g., 5%)
This value is assigned based on general knowledge or (in other
settings) could be estimated from sample data by methods like
deconvolution using TA data of other genes.
= fold change difference between ùëáùê¥ùêµ ùëêùëíùëôùëôùë† and ùëáùê¥ùëäùêµ ,
ùëáùê¥
= ùëáùê¥ùêµ ùëêùëíùëôùëôùë†
ùëäùêµ

This is the observed difference in expression of a gene in WB and
purified B cell samples.
A general model of TA in WB would be

ùëáùê¥ùëäùêµ = ùëÉùêµ ùëêùëíùëôùëôùë† ‚àô ùëáùê¥ùêµ ùëêùëíùëôùëôùë† + (1 ‚àí ùëÉùêµ ùëêùëíùëôùëôùë† ) ‚àô ùëáùê¥ùëúùë°‚Ñéùëíùëü ùëêùëíùëôùëôùë†
Here ùëáùê¥ùëúùë°‚Ñéùëíùëü ùëêùëíùëôùëôùë† is a hypothetical parameter representing a weighted average of TA of all other celltypes based on their respective proportional counts. It is a term that is not actually determined or measured but
is used to present a general model.
In order to understand the relationship between % contribution of TA in a cell mixture (WB) by a specified celltype (B cells), which is expressed as Y-axis in supplementary figure 1,
% TA contribution in a WB sample by B cells =

ùëÉùêµ ùëêùëíùëôùëôùë† ‚àô ùëáùê¥ùêµ ùëêùëíùëôùëôùë†
ùëÉùêµ ùëêùëíùëôùëôùë† ‚àô ùëáùê¥ùêµ ùëêùëíùëôùëôùë†
=
= ùëÉùêµ ùëêùëíùëôùëôùë† ‚àô ùëã
ùëáùê¥ùêµ ùëêùëíùëôùëôùë†
ùëáùê¥ùëäùêµ
ùëã
The expression indicates that the relationship between % TA contribution and fold-change difference (X)
between specified cell type and WB is linear with the slope defined by the proportional cell count of that cell
type.
Supplementary figure 1 shows such a relationship for two scenarios, B cells in WB (given proportional cell
count as 5%) and B cells in PBMC (given proportion cell count as 10%). Genes with 10-folds or higher
expression (TA) in purified B cells than WB would have B cells contributing at least 50% of transcripts in the
WB samples. Similarly, for genes with more than 5-folds or higher expression (TA) in purified B cells than
PBMC, at least half of those transcripts in PBMC would originate from B cells. These fold-change criteria are
P a g e 8 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

useful to define cell-type informative genes, which could be potentially estimated directly in the cell-mixture
sample without the need of prior cell purification.

Supplementary figure 1 shows such a relationship for two scenarios, B cells in WB (given
proportional cell count as 5%) and B cells in PBMC (given proportion cell count as 10%).
An RNAseq dataset (GSE45764) had expression data for samples of purified B lymphocytes with PBMC.
Therefore, the datasets were used to identify B lymphocyte informative genes with the given fold-change
greater than 5X. Shortlisted potential B lymphocyte informative genes and their biological coefficient of
variation (CV%) are shown in supplementary table 1. TA of selected genes were extracted from these datasets
for further analysis for their performance as predictors of vaccination response.
To identify B lymphocyte reference genes among B lymphocyte informative genes
Biological variation was determined for all B lymphocyte informative genes and expressed in the coefficient of
variation % (CV%) in the purified B lymphocyte samples. Those genes with the least CV% were selected as
potential B lymphocyte reference genes, which would be used as the denominator in the new biomarker
parameter (called Direct LS-TA) to infer B lymphocyte expression directly using the cell-mixture samples (WB
or PBMC) data.
A new B-lymphocyte biomarker that can be directly measured in whole blood, Direct B lymphocyte LS-TA
Instead of using conventional housekeeping genes (like GAPDH, UBC) as the denominator in the expression
parameter, another cell-type informative gene has to be used as the denominator in the new Direct LS-TA
biomarker for B lymphocytes. It is because conventional housekeeping genes are produced by all the different
cell-types in the cell mixture, so it only represents the total cell count of all those various cell-types present in
the cell mixture sample but does not represent the variation of cell count of B lymphocyte. Therefore, the
normalization factor (or denominator) must also be a cell-type informative gene with an additional feature of
having a stable expression which could be measured as CV%.
P a g e 9 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

This new biomarker, Direct B lymphocyte leukocyte subpopulation transcript abundance (LS-TA), is derived
from the ratio of TAs of a B lymphocytes target gene and a B lymphocyte reference gene which can be directly
quantified from cell-mixture samples without the need to purify B lymphocyte. As log transformation had been
applied, this new biomarker parameter was calculated as the difference (subtraction) between the B lymphocyte
informative target gene and the B lymphocyte informative reference gene. We focused on two reference genes
here (TNFRSF13C and FCRLA), as they had the same low level of CV% with other recognized B lymphocytespecific genes (e.g., CD19, CD22). Therefore the expression of Direct LS-TA is represented as :
Direct B lymphocyte-LSTA of TNFRSF17 = log(TNFRSF17) - log(TNFRSF13C).
The dataset GSE45764 provided RNA sequencing expression data of paired PBMC and purified B lymphocytes
samples taken at the same time. For each potential B lymphocyte informative target genes, they were paired up
with the B lymphocyte reference genes (TNFRSF13C and FCRLA) to obtain its Direct B lymphocyte LS-TA
results. The ability of Direct B lymphocyte LS-TA results in reflecting the TA of the same target gene in
purified B is evaluated by the correlation between Direct B lymphocyte LS-TA measured in the PBMC samples
with TA of target genes in the purified B lymphocytes. Pearson‚Äôs correlation coefficient (r ) was used. A
conventional housekeeping gene (e.g., RPL32) was used to control for different numbers of B cells in the
purified B cell samples (e.g., X-axis in Figure 3).
Using the dataset GSE45764, Pearson‚Äôs correlation coefficient (r ) of all shortlisted B lymphocyte informative
genes were determined, and only those with r > 0.85 were further analyzed for their differential expression
between R and NR groups. They represented those B cells target genes that could be reliably inferred from a
cell-mixture sample. Thus, they can be efficiently determined in routine clinical samples, and the tedious
procedures of cell purification can be eliminated.
In addition, a superseries (GSE59635, GSE59654, GSE59743) contain microarray expression data of paired
PMBC and purified lymphocytes samples. They are also used to confirm the list of B lymphocyte informative
genes, reference genes, and the performance of Direct B lymphocyte LS-TA of selected target genes.

Meta-analysis of differentially expressed B lymphocytes LS-TA genes in other datasets
To have a better idea of the reproducibility or replication of these findings, meta-analyses were performed for
these 4 Direct B lymphocyte LS-TA biomarkers with PBMC data in a collection of datasets which were
performed on different platforms (including Affymetrix and Illumina microarrays).
Target gene of B lymphocyte
TNFRSF17
TXNDC5

Direct B lymphocyte LS-TA biomarkers using PBMC data
TNFRSF17: TNFRSF13C
TNFRSF17: FCRLA
TXNDC5: TNFRSF13C
TXNDC5: FCRLA

Each dataset was downloaded from GEO. Direct LS-TA results were determined from expression intensities of
the target genes and reference genes that had been pickup in the discovery dataset. Fixed effect meta-analysis
was performed using R package meta.

P a g e 10 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Data analysis and Statistic methods
Microarray datasets were checked if they had been normalized by RMA normalization or quantile
normalization. All data were also log-transformed with base 2. Quality check of datasets included a check for
outline by Mahalanobis distance metrics (‚ÄúMahalanobis Distance,‚Äù 2020) using (1) a list of common
housekeeping genes and (2) a list of recognized cell-type-specific genes. Samples in a dataset are defined as
outliners and removed if they both failed the outliner tests in Mahalanobis distance metrics of (1) and (2). An
example of outliner identification in a dataset GSE59654 is shown in supplementary figure 2.
Statistics analyses were performed with R packages, including plotROC, meta, and stats.

Supplementary Figure 2. Example of outliner samples in GSE59654, which are labeled as
outline by Mahalanobis distance metrics based on (A) a list of housekeeping genes and (B) a
P a g e 11 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

list of leukocyte cell-type-specific genes. The three outliner samples called in both (A) and (B)
are shown as red symbols on (C) scatter plots of housekeeping genes.

Results and Discussion
Shortlisted B lymphocyte informative genes and reference genes
The RNA-seq dataset GSE45764 has both PBMC and purified B cell samples from 5 individuals over multiple
days. Given a cell count proportion of 10%, genes expressed more than five-fold higher in purified B
lymphocytes than in cell-mixture samples could be used as lymphocyte informative genes. Shortlisted potential
B lymphocyte informative genes are shown in Table 2, together with their biological CV% in the purified cell
samples. A list of B lymphocyte informative genes with high expression and their biological CV% in PBMC
was provided in supplementary table 1.
Among the genes with the least CV% were well-recognized B lymphocyte markers, like CD19, CD20
(MS4A1), and CD22. Interestingly, TNFRSF13C and FCRLA had similar CV% with those recognized B cellspecific markers. Therefore, they were further explored as B lymphocyte reference genes and used as the
denominator for the new Direct LS-TA ratio biomarker to predict vaccination response.
Table 2. Shortlisted potential B lymphocyte informative genes in RNA-seq dataset GSE45764. Cell-type
informative reference genes could be identified among those with low CV%. Two genes stand out among peers
of other well-recognized B cell markers, TNFRSF13C and FCRLA, which are further analyzed as B cell
informative reference genes in this manuscript.
Gene symbol
Expression fold change between CV% in purified B lymphocyte
purified B lymphocytes and
samples
WB samples (X, folds)
HLA-DOB
13.360
11%
CD19
15.140
15%
CD79B
10.930
15%
CD79A
15.560
15%
BANK1
15.670
16%
TNFRSF13C
14.420
16%
MS4A1
16
17%
BLK
16
18%
CD22
16.340
18%
FCRLA
14.830
20%
FCER2
14.220
24%
TNFRSF13B
16.910
26%
TCL1A
13.550
30%
TNFRSF17
12.640
62%
JCHAIN
11.390
70%
TXNDC5
10.560
103%

P a g e 12 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Using Direct determination of B lymphocyte (LS-TA) in PBMC to represent expression (TA) of targeted
gene in purified B lymphocytes
In the dataset GSE45764, purified B lymphocytes were collected from 5 individuals over multiple days together
with PBMC samples. Therefore, the correlation between new Direct LS-TA biomarkers in PBMC samples
could be used to assess its performance to represent expression (TA) of the targeted gene in purified B
lymphocytes.
Figure 3 and supplement figure 3 show the performance of the Direct B lymphocyte LS-TA of TNFRSF17
measured in PBMC as a biomarker reflecting TNFRSF17 gene expression in purified B lymphocytes. Direct
LS-TA of TNFRSF17 were shown on Y-axis with the expression level of that gene in paired purified B
lymphocytes shown on the X-axis. The results confirm that Direct LS-TA TNFRSF17 is a reliable indicator of
its expression in purified B lymphocytes. For this example, conventional housekeeping genes were used to
normalize results obtained from purified B lymphocyte samples only.
Similarly, Direct LS-TA for another target gene (TXNDC5) in PBMC could represent TA expression levels in
purified B lymphocytes. This is shown in both RNA-seq data and microarray data. With such a strong
correlation, Direct LS-TA quantification was applied to other vaccination response dataset in which only PBMC
samples were collected for gene expression analysis. In fact, the great majority of vaccination response datasets
did not have expression information of purified leukocyte subpopulation cell-types; the application of Direct
LS-TA method provides a mean to analyze cell-type specific TA in such datasets.

P a g e 13 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 3. High level of correlation between new biomarker, Direct LS-TA biomarker of target
gene TNFRSF17 by measuring TAs of 2 genes (TNFRSF17 and TNFRSF13C) in PBMC
samples (Y-axis) and TA of purified B lymphocytes (X-axis). R2=0.82 (p-value < 2.2 x 10^16)

P a g e 14 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Supplementary Figure 3. High level of correlation between new biomarker, Direct LS-TA biomarker of target
gene TNFRSF17 by measuring TAs of 2 genes (TNFRSF17 and TNFRSF13C) in PBMC samples (Y-axis)
and TA of purified B lymphocytes (X-axis).

Not only B-lymphocyte expression of TNFRSF17 could be gauged in a peripheral blood sample, but a list of Blymphocyte informative genes could also be analyzed using the Direct LS-TA method. Table 3 shows the list of
B-lymphocyte target genes whose TA could be estimated in PBMC, and Direct LS-TA biomarker of these
target genes had a very good correlation with their TA in purified B lymphocytes. Supplement table2 also
include results using FCRLA as the Direct LS-TA reference gene.
Many target genes encode for part of the antibody (like IGHG1, IGLL5). Other genes were MZB1, FCRL5,
TNFRSF17, and TXNDC5 which were described in B lymphocyte. The function of 2 other genes, DSP and
COCH, was not certain.
Table 3. B-lymphocyte target genes that can be reliably measured in PBMC without cell purification
B lymphocyte
B lymphocyte informative
Pearson‚Äôs correlation coefficient
informative target gene
reference gene
between Direct LSTA assay in PBMC and
isolated B cell target gene expression

IGHG1
DSP
IGHG3
MZB1
IGHA1
IGLL5
JCHAIN
FCRL5
IGHA2

TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C

0.96
0.94
0.94
0.93
0.93
0.93
0.92
0.91
0.9
P a g e 15 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

IGHM
TNFRSF17
TXNDC5
IGKC
COCH

TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C
TNFRSF13C

0.9
0.9
0.88
0.86
0.85

Differential expression of B lymphocyte LS-TA at first week after vaccination
With this new B lymphocyte biomarker available, it is now possible to estimate the expression of B lymphocyte
as a response to vaccination using the expression data of PBMC samples (see the list in table 1). Dataset
GSE59654 (influenza vaccine) was used as an explorative dataset to visualize any differential gene expression
(as determined by LS-TA) at Day 7 between the two groups of R and NR. This dataset was selected as it had the
largest sample size. Figure 4A shows that R had a significantly higher level of Direct B lymphocyte LS-TA of
TNFRSF17 than NR (Wilcoxon test, p-value =0.037). Similarly, the increment of Direct B lymphocyte LS-TA
of TNFRSF17 from the day of vaccination (Day 0) to Day 7 was also highly significant in a paired Wilcoxon
test (Figure 4B, p-value =0.024). This difference was due to the fact that most responders had an increase of
TNFRSF17 of similar magnitude from Day 0 to Day 7 while it was absent in non-responders (Figure 4B).

Figure 4. Based on the explorative dataset, GSE59654, (A) Day 7 Direct B-lymphocyte LS-TA
results of TNFRSF17 in responder (R ) and non-responder (NR) groups. (B) Paired Day 0 and
Day 7 change in Direct LS-TA expressed as multiple of median (MoM) using Day 0 group
median.
Both the differential Direct B lymphocyte LS-TA of TXNDC5 at Day 7 and the increment from Day 0 to Day 7
were also statistically significant between responders and non-responders (Figure 5).
P a g e 16 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 5. (A) Day 7 Direct B-lymphocyte LS-TA results of another target gene TXNDC5 in
responder (R ) and non-responder (NR) groups. (B) Paired Day 0 and Day 7 change in Direct
LS-TA expressed as multiple of median (MoM) using Day 0 group median.

Meta-analysis of differentially expressed B lymphocytes LS-TA genes in other datasets
To have a better idea of the reproducibility or replication of these findings, meta-analyses were performed for
these 4 Direct B lymphocyte LS-TA biomarkers with PBMC data in a collection of datasets which were
performed on different platforms (including Affymetrix and Illumina microarrays).
Target gene of B lymphocyte
TNFRSF17
TXNDC5

Direct B lymphocyte LS-TA biomarkers using PBMC data:
(Ratio of TA of 2 genes as LS-TA biomarker)
TNFRSF17: TNFRSF13C
TNFRSF17: FCRLA
TXNDC5: TNFRSF13C
TXNDC5: FCRLA

The meta-analysis on TNFRSF17 could be performed on 7 PBMC datasets (Table 1 and Figure 6). Regardless
of having TNFRSF13C or FCRLA as the reference gene, the meta-analysis confirmed an overall differential
level of Direct LS-TA TNFRSF17 on Day 7 between NR and R groups. In fact, the overall effects were similar
in magnitude, and their SMD ranged from 0.6 and 0.8. When TXNDC5 was used as the target gene, similar
results were obtained. It suggests that either TNFRSF17 or TXNDC5 and their Direct B lymphocyte LS-TA
could be used as a biomarker for vaccination response.
P a g e 17 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 6. Meta-analysis of the Day7 results of Direct B lymphocyte-LSTA of TNFRSF17 and TXNDC5
using TNFRSF13C or FCRLA as a reference gene in PBMC datasets. Day 7 Direct B lymphocyte-LSTA was
significantly higher among the responder groups with an overall effect SMD of 0.6 to 0.8. The specific probe
sets used in the calculation of Direct LS-TA are also shown in the table following the gene symbols. (A) and
(B) are the results of Direct LS-TA of TNFRSF17 using two different B lymphocyte reference genes
(TNFRSF13C and FCRLA). (C) and (D) show the Direct LS-TA results of TXNDC5 using these 2 B
lymphocyte reference genes. The specific probe sets used in the calculation of Direct LS-TA are also shown
in the table following the gene symbols.
P a g e 18 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Similarly, the increment from Day 0 to Day 7 was analyzed by meta-analysis in these datasets. The overall
effects of greater increment in the responders were confirmed (Figure 7).

Figure 7. Meta-analysis of the differential increment from Day 0 to Day 7 of Direct B lymphocyte-LSTA
between R and NR groups. (A) and (B) are the results of the differential increment of Direct LS-TA of
TNFRSF17 using two different B lymphocyte reference genes (TNFRSF13C and FCRLA). (C) and (D) are the
results of the differential increment of the Direct LS-TA results of TXNDC5 using these 2 B lymphocyte
reference genes. Direct B lymphocyte-LSTA showed significantly higher increments among the responders
P a g e 19 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

with an overall effect SMD of between 0.62 to 0.77. The specific probe sets used in the calculation of Direct
LS-TA are also shown in the table following the gene symbols.

Evaluation of the performance by Receiver operator curve (ROC) analysis
Receiver operator curve (ROC) analysis was used to evaluate the test performance of Direct LS-TA as an early
(first-week) predictive biomarker for subsequent response status at Day 28 after vaccination. As the study
group case-mix were different among studies, the AUC was also different (Figure 7). However, all studies had
AUC greater than 0.5, and those of a few studies were higher than 0.8. In some settings, the sensitivity could be
0.8 or higher, while the specificity was around 0.5. On the other hand, a high specificity of the range of 0.8-0.9
could be targeted if a lower sensitivity down to 0.6 is allowed. Figure 8 shows the ROC analysis of the
increment of Direct B lymphocyte LS-TA as a biomarker. Again, most studies have AUC above 0.6.
The exact cut-off point to be used depends on the purpose and rationale of the test. The applications of this
method are wide. For example, if the vaccine is unstable, the producer would want to know early if any batch of
the vaccine had degraded; this test would provide the answer as early as seven days after administration of the
batch. In this scenario, a group of vaccine recipients is monitored for the Day 7 increase in Direct B lymphocyte
LS-TA. A high sensitivity cut-off value will be used, so most of the recipients are expected to reach the cut-off
value indicating that the vaccine is active. If the number or percentage of recipients showing an increase in
Direct B lymphocyte LS-TA on Day 7 is less than a pre-defined percentage which is available on the ROC
curve for any specific cut-off value. Degradation of the batch of vaccine would be possible and remedial work
could be implemented early rather than waiting for the Day 28 antibody response.
On the other hand, Direct B-lymphocyte LS-TA test could be used for personalized vaccination in which an
individual wants to know his subsequent vaccination response early after vaccination.
A high specificity cut-off value will be used in this scenario. Although only around 60% of the responder
recipients will achieve this cut-off value, the false position rate is low. This will support a high positive
predictive value, so recipients with positive Direct B-lymphocyte LS-TA results would be very likely to be
responders. The consequence of a negative Direct B-lymphocyte LS-TA is a requirement of doing a follow-up
antibody test on Day 28. The high positive rate of Day 7 Direct B lymphocyte LS-TA will allow the majority of
responders to be given the results early.

P a g e 20 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 8. ROC curves of Day 7 Direct B lymphocyte-LSTA of TNFRSF17 and TXNDC5
using two different B lymphocyte informative reference genes (TNFRSF13C and FCRLA).
The performance of the single cell-type-specific biomarker parameters Direct LSTA were
analyzed by ROC with Responder as a positive outcome.

P a g e 21 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Figure 9. ROC curves of Day 0 to Day 7 increment of Direct B lymphocyte-LSTA of
TNFRSF17 and TXNDC5 using two different B lymphocyte informative reference genes
(TNFRSF13C and FCRLA). The performance of the single cell-type-specific biomarker
parameters Direct LSTA were analyzed by ROC with Responder as a positive outcome.

P a g e 22 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Summary
A simple TA test to determine B lymphocyte gene expression in PBMC samples that could be readily
incorporated into the routine clinical laboratory is introduced here. This B lymphocyte Direct LS-TA provides a
valid reflection of gene expression of purified B lymphocyte without the need to isolate B lymphocytes from
blood cells. It could be used as an early prediction of seroconversion status after influenza vaccination. During
the COVID-19 epidemic, a vaccination campaign is just underway. Due to the same mechanism of antibody
production, Direct B lymphocyte LS-TA will be a very useful companion assay for the practice of personalized
vaccination or as a biological quality control method for monitoring of vaccine efficiency and degradation.

Conflict of interest statements
Patent application pending.
D Huang and A Liu are employees of Cytomics Ltd.
KS Leung and N Tang are share-holders of Cytomics Ltd.
Cytomics Ltd holds a license to use a patent related to Direct LS-TA assay.

P a g e 23 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

References
Avey, S., Mohanty, S., Chawla, D. G., Meng, H., Bandaranayake, T., Ueda, I., Zapata, H. J., Park, K., Blevins,
T. P., Tsang, S., Belshe, R. B., Kaech, S. M., Shaw, A. C., & Kleinstein, S. H. (2020). Seasonal
Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older
Adults. Journal of Immunology (Baltimore, Md.: 1950), 204(6), 1661‚Äì1673.
https://doi.org/10.4049/jimmunol.1900922
Avila Cobos, F., Alquicira-Hernandez, J., Powell, J. E., Mestdagh, P., & De Preter, K. (2020). Benchmarking of
cell type deconvolution pipelines for transcriptomics data. Nature Communications, 11(1), 5650.
https://doi.org/10.1038/s41467-020-19015-1
Black, S., Bloom, D. E., Kaslow, D. C., Pecetta, S., & Rappuoli, R. (2020). Transforming vaccine development.
Seminars in Immunology, 50, 101413. https://doi.org/10.1016/j.smim.2020.101413
Blanco, E., P√©rez-Andr√©s, M., Arriba-M√©ndez, S., Contreras-Sanfeliciano, T., Criado, I., Pelak, O., SerraCaetano, A., Romero, A., Puig, N., Remesal, A., Canizales, J. T., L√≥pez-Granados, E., Kalina, T., Sousa,
A. E., Zelm, M. van, Burg, M. van der, Dongen, J. J. M. van, & Orfao, A. (2018). Age-associated
distribution of normal B-cell and plasma cell subsets in peripheral blood. Journal of Allergy and Clinical
Immunology, 141(6), 2208-2219.e16. https://doi.org/10.1016/j.jaci.2018.02.017
Casey, R. M., Harris, J. B., Ahuka-Mundeke, S., Dixon, M. G., Kizito, G. M., Nsele, P. M., Umutesi, G., Laven,
J., Kosoy, O., Paluku, G., Gueye, A. S., Hyde, T. B., Ewetola, R., Sheria, G. K. M., Muyembe-Tamfum,
J.-J., & Staples, J. E. (2019). Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever
Outbreak‚ÄîFinal Report. The New England Journal of Medicine, 381(5), 444‚Äì454.
https://doi.org/10.1056/NEJMoa1710430
Committee for Medicinal Products for Human Use. (1997). Note for guidance on harmonisation of
requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products,
Brussels, Belgium (1997). https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidanceharmonisation-requirements-influenza-vaccines_en.pdf
Ding, Y., Zhou, L., Xia, Y., Wang, W., Wang, Y., Li, L., Qi, Z., Zhong, L., Sun, J., Tang, W., Liang, F., Xiao,
H., Qin, T., Luo, Y., Zhao, X., Shu, Z., Ru, Y., Dai, R., Wang, H., ‚Ä¶ Zhao, X. (2018). Reference values
for peripheral blood lymphocyte subsets of healthy children in China. Journal of Allergy and Clinical
Immunology, 142(3), 970-973.e8. https://doi.org/10.1016/j.jaci.2018.04.022
Henn, A. D., Wu, S., Qiu, X., Ruda, M., Stover, M., Yang, H., Liu, Z., Welle, S. L., Holden-Wiltse, J., Wu, H.,
& Zand, M. S. (2013). High-Resolution Temporal Response Patterns to Influenza Vaccine Reveal a
Distinct Human Plasma Cell Gene Signature. Scientific Reports, 3(1), 2327.
https://doi.org/10.1038/srep02327
Horns, F., Dekker, C. L., & Quake, S. R. (2020). Memory B Cell Activation, Broad Anti-influenza Antibodies,
and Bystander Activation Revealed by Single-Cell Transcriptomics. Cell Reports, 30(3), 905-913.e6.
https://doi.org/10.1016/j.celrep.2019.12.063
Mahalanobis distance. (2020). In Wikipedia.
https://en.wikipedia.org/w/index.php?title=Mahalanobis_distance&oldid=995007639
Mo, Z., Nong, Y., Liu, S., Shao, M., Liao, X., Go, K., & Lavis, N. (2017). Immunogenicity and safety of a
trivalent inactivated influenza vaccine produced in Shenzhen, China. Human Vaccines &
Immunotherapeutics, 13(6), 1272‚Äì1278. https://doi.org/10.1080/21645515.2017.1285475
Monaco, G., Lee, B., Xu, W., Mustafah, S., Hwang, Y. Y., Carr√©, C., Burdin, N., Visan, L., Ceccarelli, M.,
Poidinger, M., Zippelius, A., Pedro de Magalh√£es, J., & Larbi, A. (2019). RNA-Seq Signatures
Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. Cell
Reports, 26(6), 1627-1640.e7. https://doi.org/10.1016/j.celrep.2019.01.041
P a g e 24 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Nakaya, H. I., Wrammert, J., Lee, E. K., Racioppi, L., Marie-Kunze, S., Haining, W. N., Means, A. R., Kasturi,
S. P., Khan, N., Li, G.-M., McCausland, M., Kanchan, V., Kokko, K. E., Li, S., Elbein, R., Mehta, A.
K., Aderem, A., Subbarao, K., Ahmed, R., & Pulendran, B. (2011). Systems biology of vaccination for
seasonal influenza in humans. Nature Immunology, 12(8), 786‚Äì795. https://doi.org/10.1038/ni.2067
Pezeshki, A., Ovsyannikova, I. G., McKinney, B. A., Poland, G. A., & Kennedy, R. B. (2019). The role of
systems biology approaches in determining molecular signatures for the development of more effective
vaccines. Expert Review of Vaccines, 18(3), 253‚Äì267. https://doi.org/10.1080/14760584.2019.1575208
Rogers, L. R. K., de los Campos, G., & Mias, G. I. (2019). Microarray Gene Expression Dataset Re-analysis
Reveals Variability in Influenza Infection and Vaccination. Frontiers in Immunology, 10.
https://doi.org/10.3389/fimmu.2019.02616
Shen-Orr, S. S., & Gaujoux, R. (2013). Computational deconvolution: Extracting cell type-specific information
from heterogeneous samples. Current Opinion in Immunology, 25(5), 571‚Äì578.
https://doi.org/10.1016/j.coi.2013.09.015
Shen-Orr, S. S., Tibshirani, R., Khatri, P., Bodian, D. L., Staedtler, F., Perry, N. M., Hastie, T., Sarwal, M. M.,
Davis, M. M., & Butte, A. J. (2010). Cell type-specific gene expression differences in complex tissues.
Nature Methods, 7(4), 287‚Äì289. https://doi.org/10.1038/nmeth.1439
Thakar, J., Mohanty, S., West, A. P., Joshi, S. R., Ueda, I., Wilson, J., Meng, H., Blevins, T. P., Tsang, S.,
Trentalange, M., Siconolfi, B., Park, K., Gill, T. M., Belshe, R. B., Kaech, S. M., Shadel, G. S.,
Kleinstein, S. H., & Shaw, A. C. (2015). Aging-dependent alterations in gene expression and a
mitochondrial signature of responsiveness to human influenza vaccination. Aging, 7(1), 38‚Äì52.
https://doi.org/10.18632/aging.100720
Tsang, J. S., Schwartzberg, P. L., Kotliarov, Y., Biancotto, A., Xie, Z., Germain, R. N., Wang, E., Olnes, M. J.,
Narayanan, M., Golding, H., Moir, S., Dickler, H. B., Perl, S., Cheung, F., Baylor HIPC Center, & CHI
Consortium. (2014). Global analyses of human immune variation reveal baseline predictors of
postvaccination responses. Cell, 157(2), 499‚Äì513. https://doi.org/10.1016/j.cell.2014.03.031
Uhlen, M., Karlsson, M. J., Zhong, W., Tebani, A., Pou, C., Mikes, J., Lakshmikanth, T., Forsstr√∂m, B., Edfors,
F., Odeberg, J., Mardinoglu, A., Zhang, C., von Feilitzen, K., Mulder, J., Sj√∂stedt, E., Hober, A.,
Oksvold, P., Zwahlen, M., Ponten, F., ‚Ä¶ Brodin, P. (2019). A genome-wide transcriptomic analysis of
protein-coding genes in human blood cells. Science (New York, N.Y.), 366(6472).
https://doi.org/10.1126/science.aax9198
Weiner, J., Lewis, D. J. M., Maertzdorf, J., Mollenkopf, H.-J., Bodinham, C., Pizzoferro, K., Linley, C.,
Greenwood, A., Mantovani, A., Bottazzi, B., Denoel, P., Leroux-Roels, G., Kester, K. E., Jonsdottir, I.,
van den Berg, R., Kaufmann, S. H. E., & Del Giudice, G. (2019). Characterization of potential
biomarkers of reactogenicity of licensed antiviral vaccines: Randomized controlled clinical trials
conducted by the BIOVACSAFE consortium. Scientific Reports, 9(1), 20362.
https://doi.org/10.1038/s41598-019-56994-8

P a g e 25 | 25

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424767; this version posted December 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

